Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Archaeological digs at UNC's New East yield centuries-old relics
On a sunny morning in late April, a group of North Carolina faculty and students hunched down on the ground outside New East and sifted...
Wed Nov 12, 2025

James Blizzard is living out his Carolina dream
When James Rolf Blizzard ’24 was 5 years old, his dad took him to a Carolina basketball game at the Smith Center. There Rolf Blizzard...
Mon Nov 10, 2025

Carolina Brewery Celebrates 30 Years
Few Tar Heels have a pedigree as lengthy as Robert Poitras, a fourth-generation UNC alum who grew up tailgating at Kenan Stadium and cheering on...
Sun Nov 9, 2025

Meet 10 Tar Heel military heroes
UNC has a longstanding history of supporting veterans on campus. Before or after they served their country, they spent time in Chapel Hill learning from...
Sat Nov 8, 2025